Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LTCR-N1-1
- Development stage
- Unknown
- Lead developer
- Lion TCR
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
LTCR-N1-1 is an autologous T-cell receptor engineered T-cell (TCR-T) therapy developed by Lion TCR for the treatment of Epstein-Barr Virus (EBV)-associated malignancies, such as nasopharyngeal carcinoma. The therapy utilizes the LioCyx-M platform, which involves isolating a patient's own T cells and using mRNA electroporation to transiently express TCRs specific to EBV antigens. This approach allows the engineered T cells to recognize and eliminate EBV-infected tumor cells. The use of mRNA transfection provides a safety advantage by ensuring transient expression of the TCR, which may reduce the risk of long-term off-target toxicities compared to permanent viral vector-based modifications. LTCR-N1-1 is currently being evaluated in early-phase clinical trials for EBV-related cancers.
- Brand names
- LioCyx-M
- Other names
- EBV-targeting TCR-TLion TCR EBV antigen-TCR-T cell therapy
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on LTCR-N1-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LTCR-N1-1.